Abstract
Protein-protein and protein-nucleic acid interactions are involved in many regulatory cellular pathways, playing a key role in cell growth and proliferation, as well as in the progression and development of various diseases such as infectious diseases. Especially in the anti-AIDS research, protein-protein and protein-nucleic acid complexes are being considered as promising targets for pharmaceutical interventions aimed at overcoming the drug resistance observed for most of the classic enzyme inhibitors. Consequently, more and more protein-protein and protein-nucleic acid interaction inhibitors have being identified and developed as candidate agents for antiretroviral therapy. Here, we review the state of the art in the discovery and development of protein-protein and protein-nucleic acid interaction inhibitors that block the main steps of the HIV-1 replication cycle, giving a medicinal chemistry-oriented view of strategies for inhibiting these regulatory interactions that are involved in the entry process, in the dimerization of reverse transcriptase and protease enzymes, and in the activity of the nucleocapsid protein by means of small molecular potential therapeutic agents.
Keywords: AIDS, entry, gp120-CD4, HIV-1, nucleocapsid protein NCp7, reverse transcriptase dimerization, protein-nucleic acid interactions, protein-protein interactions, protease, cytotoxicity
Current Pharmaceutical Design
Title: Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy
Volume: 17 Issue: 33
Author(s): Mattia Mori, Fabrizio Manetti and Maurizio Botta
Affiliation:
Keywords: AIDS, entry, gp120-CD4, HIV-1, nucleocapsid protein NCp7, reverse transcriptase dimerization, protein-nucleic acid interactions, protein-protein interactions, protease, cytotoxicity
Abstract: Protein-protein and protein-nucleic acid interactions are involved in many regulatory cellular pathways, playing a key role in cell growth and proliferation, as well as in the progression and development of various diseases such as infectious diseases. Especially in the anti-AIDS research, protein-protein and protein-nucleic acid complexes are being considered as promising targets for pharmaceutical interventions aimed at overcoming the drug resistance observed for most of the classic enzyme inhibitors. Consequently, more and more protein-protein and protein-nucleic acid interaction inhibitors have being identified and developed as candidate agents for antiretroviral therapy. Here, we review the state of the art in the discovery and development of protein-protein and protein-nucleic acid interaction inhibitors that block the main steps of the HIV-1 replication cycle, giving a medicinal chemistry-oriented view of strategies for inhibiting these regulatory interactions that are involved in the entry process, in the dimerization of reverse transcriptase and protease enzymes, and in the activity of the nucleocapsid protein by means of small molecular potential therapeutic agents.
Export Options
About this article
Cite this article as:
Mori Mattia, Manetti Fabrizio and Botta Maurizio, Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy, Current Pharmaceutical Design 2011; 17 (33) . https://dx.doi.org/10.2174/138161211798220972
DOI https://dx.doi.org/10.2174/138161211798220972 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of WHO II/III Gliomas by 16 Prognostic-related Gene Signatures using Machine Learning Methods
Current Medicinal Chemistry Toxicological Profile of Therapeutic Nanodelivery Systems
Current Drug Metabolism Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Synthetic Lethality to Overcome Cancer Drug Resistance
Current Medicinal Chemistry Differences in Phosphorylated Histone H2AX Foci Formation and Removal of Cells Exposed to Low and High Linear Energy Transfer Radiation
Current Genomics Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Structural Basis and Therapeutic Implication of the Interaction of CCN Proteins with Glycoconjugates
Current Pharmaceutical Design Diarylurea: A Privileged Scaffold in Drug Discovery and Therapeutic Development
Current Medicinal Chemistry Targeting miR-21 Induces Autophagy and Chemosensitivity of Leukemia Cells
Current Drug Targets DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Targeting Oncogenes and Tumor Suppressors genes to Mitigate Chemoresistance
Current Cancer Drug Targets Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy ZIP4 is a Novel Diagnostic and Prognostic Marker in Human Pancreatic Cancer: A Systemic Comparison Between EUS-FNA and Surgical Specimens
Current Molecular Medicine Poly(ADP-Ribosylation): Beneficial Effects of Its Inhibition
Current Enzyme Inhibition Endothelin Receptors, Mitochondria and Neurogenesis in Cerebral Ischemia
Current Neuropharmacology Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases
Current Cancer Drug Targets Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy
Current Cancer Drug Targets Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Molecular Biology of Nucleoside Transporters and their Distributions and Functions in the Brain
Current Topics in Medicinal Chemistry Indole Compounds Against Breast Cancer: Recent Developments
Current Drug Targets